United States to India Pharmaceutical Import

The pharmaceutical trade corridor between the United States and India has experienced significant growth over the past two decades. In 2005, the bilateral pharmaceutical trade was valued at approximately $500 million, with around 5,000 shipments. By 2025, this figure had escalated to $2.7 billion, encompassing 27,607 shipments. This expansion underscores the increasing interdependence of the two nations in the pharmaceutical sector.

Key milestones in this evolution include the establishment of the U.S.-India Trade Policy Forum in 2005, aimed at enhancing bilateral trade relations. The signing of the U.S.-India Civil Nuclear Agreement in 2008 also paved the way for deeper economic collaborations, indirectly benefiting sectors like pharmaceuticals. Additionally, India's participation in the World Trade Organization (WTO) since 1995 has facilitated smoother trade processes, including the import of pharmaceutical products from the U.S.

The United States plays a pivotal role in India's pharmaceutical imports, accounting for a substantial share of the market. In 2025, the U.S. supplied a diverse range of pharmaceutical products to India, including vaccines, serums, and specialized drugs. Notably, vaccines alone constituted 34.9% of the total import value, highlighting the critical importance of immunological products in the bilateral trade.

India's importation of these products from the U.S. is driven by the need for advanced medical treatments and technologies not readily available domestically. The U.S. pharmaceutical industry is renowned for its innovation and high-quality standards, making it a preferred source for India's healthcare requirements.

Between 2024 and 2026, several developments have influenced the pharmaceutical trade between the U.S. and India. In March 2025, the Indian Pharmaceutical Alliance (IPA) advocated for the reduction of import duties on U.S. pharmaceutical products to zero, aiming to bolster the domestic industry by lowering costs.

Additionally, in September 2025, the U.S. imposed a 100% tariff on all branded or patented pharmaceutical imports, effective October 1, 2025, unless the manufacturer is actively building a production facility in the U.S. This policy shift has significant implications for Indian drugmakers, who rely heavily on the U.S. market for generic drugs.

For U.S. companies aiming to export pharmaceutical products to India, compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations is mandatory. The process involves obtaining an import license under Form 10 of the Drugs and Cosmetics Rules, 1945, and registering the product with CDSCO under Form 41.

The registration process requires submission of comprehensive documentation, including a Certificate of Analysis (CoA) for each batch, a Good Manufacturing Practice (GMP) certificate from the exporting country, and an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT). Additionally, an authorization letter from the manufacturer or marketing authorization holder (MAH) is necessary, authorizing the Indian importer to import specific pharmaceutical products on their behalf.

India mandates that pharmaceutical products imported from the U.S. be manufactured in facilities compliant with Good Manufacturing Practice (GMP) standards as prescribed by CDSCO. The manufacturing facilities must meet specific requirements concerning premises, plant, machinery, and quality control processes. Compliance with these standards ensures the safety, efficacy, and quality of pharmaceutical products available in the Indian market.

Importing pharmaceutical products into India necessitates several key documents:

• Import License (Form 10): Issued by CDSCO, this license authorizes the importation of specific pharmaceutical products.

• Registration Certificate (Form 41): Also issued by CDSCO, this certificate confirms that the imported product is registered for sale in India.

• No Objection Certificate (NOC): Required for certain products, this certificate indicates that the product does not violate any existing patents or trademarks in India.

• Test License: Permits the import or manufacture of drugs for testing, analysis, or clinical trial purposes.

• Customs Documentation: Includes the Bill of Entry and other customs declarations necessary for clearing goods through Indian customs.

Ensuring all documentation is accurate and complete is crucial for the smooth clearance of pharmaceutical imports.

The pharmaceutical imports from the United States to India are predominantly in the categories of vaccines, serums, and specialized drugs. Vaccines alone accounted for 34.9% of the total import value, underscoring their critical role in India's healthcare system. Serums and plasma products also constitute significant portions of the imports, reflecting the demand for advanced biological products.

Specialized drugs, including Dapagliflozin, Fluticasone, and Nivolumab, are imported to address specific therapeutic needs not met by domestic products. These imports are essential for treating complex health conditions and contribute to the advancement of medical treatments in India.

India's importation of innovator drugs and novel formulations from the United States is driven by the need for advanced therapies not manufactured domestically. Products like Dapagliflozin, Fluticasone, and Nivolumab are examples of specialized drugs imported to meet specific therapeutic requirements. These imports are crucial for addressing complex health conditions and advancing medical treatments in India.

India's importation of pharmaceutical products from the United States is influenced by several factors:

• Patent Protection: The U.S. offers strong patent protection, ensuring that innovative drugs are available for import without generic competition.

• Technology Gaps: Certain advanced pharmaceutical technologies and formulations are not yet developed domestically, necessitating imports to meet healthcare needs.

• Quality Requirements: The U.S. pharmaceutical industry is renowned for its stringent quality standards, making its products highly desirable in the Indian market.

• Disease Burden: The prevalence of specific diseases in India creates a demand for specialized treatments that are often sourced from the U.S.

These factors collectively drive the sustained demand for U.S. pharmaceutical imports into India.

India imposes a 10% import duty on pharmaceutical products imported from the United States. This duty is part of the Basic Customs Duty (BCD) and is applicable to a wide range of pharmaceutical products. Additionally, the Integrated Goods and Services Tax (IGST) and health cess may apply, depending on the specific product and its classification under the Harmonized System (HS) code.

In March 2025, the Indian Pharmaceutical Alliance (IPA) proposed reducing the import duty on U.S. pharmaceutical products to zero, aiming to support the domestic industry by lowering costs.

As of March 2026, there is no Free Trade Agreement (FTA) between India and the United States specifically addressing pharmaceutical products. However, both countries are members of the World Trade Organization (WTO), which facilitates trade through agreed-upon rules and regulations. Additionally, India has been involved in discussions regarding the Regional Comprehensive Economic Partnership (RCEP), which could influence future trade dynamics, including pharmaceutical imports.

India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents by restricting the patentability of new forms of known substances unless they result in enhanced efficacy. This provision has implications for the importation of certain pharmaceutical products. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines in India, which can affect the pricing of imported drugs. Compulsory licensing provisions allow the government to grant licenses to produce patented products without the consent of the patent holder under specific circumstances, such as public health emergencies.

Pharmaceutical products imported from the United States to India are typically transported via major sea and air routes. Sea shipments often depart from ports like New York and Los Angeles, arriving at Indian ports such as Mumbai and Chennai. Air shipments are usually routed through major international airports, including John F. Kennedy International Airport (JFK) and Los Angeles International Airport (LAX), with arrivals at Indira Gandhi International Airport (DEL) in Delhi and Chhatrapati Shivaji Maharaj International Airport (BOM) in Mumbai.